Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNexus Gene Lab (BGLC) EBIT Margin (2018 - 2025)

BioNexus Gene Lab's EBIT Margin history spans 8 years, with the latest figure at 27.62% for Q3 2025.

  • For Q3 2025, EBIT Margin rose 2324.0% year-over-year to 27.62%; the TTM value through Sep 2025 reached 24.81%, down 1510.0%, while the annual FY2024 figure was 16.55%, 1000.0% up from the prior year.
  • EBIT Margin for Q3 2025 was 27.62% at BioNexus Gene Lab, down from 27.05% in the prior quarter.
  • Across five years, EBIT Margin topped out at 80.34% in Q1 2021 and bottomed at 99.01% in Q3 2023.
  • The 5-year median for EBIT Margin is 3.32% (2024), against an average of 8.08%.
  • The largest annual shift saw EBIT Margin skyrocketed 26411bps in 2021 before it crashed -9648bps in 2023.
  • A 5-year view of EBIT Margin shows it stood at 6.2% in 2021, then plummeted by -170bps to 4.32% in 2022, then soared by 362bps to 11.34% in 2023, then crashed by -245bps to 16.49% in 2024, then crashed by -67bps to 27.62% in 2025.
  • Per Business Quant, the three most recent readings for BGLC's EBIT Margin are 27.62% (Q3 2025), 27.05% (Q2 2025), and 28.94% (Q1 2025).